Titration of a vaccine stock preparation of human immunodeficiency virus type 1(SF2) in cultured lymphocytes and in chimpanzees

AIDS Research and Human Retroviruses

Volumn 12, Issue 14, 1996, Pages 1341-1348

  Murthy, Krishna K ^a   Cobb, E Kathy ^a   El Amad, Zahwa ^b   Ortega, Henry ^c   Hsueh, Frank C ^c   Satterfield, William ^d   Lee, D Rick ^d   Kalish, Marcia L ^e   Haigwood, Nancy L ^f   Kennedy, Ronald C ^g   Steimer, Kathelyn S ^b   Schultz, Alan ^h   Levy, Jay A ^c,i  

^a SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f BRISTOL MYERS SQUIBB   (United States)

^g UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CHIMPANZEE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; VACCINE PRODUCTION; VIRUS ISOLATION;

EID: 0029839394     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1996.12.1341     Document Type: Article

References (37)

1. Alter HJ, Eichberg JW, Masur H, Saxinger WC, Gallo RC, Macher AM, Lane HC, and Fauci AS: Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS. Science 1984;226:549-552.
2. Fultz PN, McClure HM, Swenson RB, McGrath CR, Brodie A, Getchell JP, Jensen FC, Anderson DC, Broderson JR, and Francis DP: Persistent infection of chimpanzees with human T-lymphotropic virus type III/LAV: A potential model for acquired immunodeficiency syndrome. J Virol 1986;58:116-124.
3. Morrow WJW, Homsy J, Eichberg JW, Krowka J, Pan L-Z, Gaston I, Legg H, Lerche N, Thomas J, and Levy JA: Long-term observation of baboons, rhesus monkeys, and chimpanzees inoculated with HIV and given periodic immunosuppressive treatment. AIDS Res Hum Retrovir 1989;5:233-245.
4. Herman PW, Groopman JE, Gregory T, Clapham P, Weiss RA, Ferriani R, Riddle L, Shimasaki C, Lucas C, Lasky LA, and Eichberg JW: HIV-1 challenge of chimpanzees immunized with recombinant gp120. Proc Natl Acad Sci USA 1988;85:5200-5204.
5. Berman PW, Gregory TJ, Riddle L, Nakamura GR, Champe MA, Porter JP, Wurm FM, Hershberg RD, Cobb EK, and Eichberg JW: Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature (London) 1990;345:622-625.
6. Fultz PN, Nara P, Barre-Sinoussi F, Chaput A, Greenberg ML, Muchmore E, Kieny M-P, and Girard M: Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science 1992;256:1687-1690.
7. Arthur LO, Bess JW Jr, Waters DJ, Pyle SW, Kelliher JC, Nara PL, Krohn K, Robey WG, Langlois AJ, Gallo RC, and Fischinger PJ: Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120. J Virol 1989;63:5046-5053.
8. Girard M, Kieny M-P, Pinter A, Barre-Sinoussi F, Nara P, Kobe H, Kusumi K, Chaput A, Reinhart T, Muchmore E, Ronco J, Kaczonek M, Garrard E, Gluckman J-C, and Fultz PN: Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci USA 1991;88:542-546.
9. Hu S-L, Fultz PN, and McClure HM: Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees. Nature (London) 1987;355:728-730.
10. Emini EA, Schleif WA, Nunberg JH, Conley AJ, Eda Y, Tokiyoshi S, Putney SD, Matsushita S, Cobb KE, Jett CM, Eichberg JW, and Murthy KK: Prevention of IUV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature (London) 1992;355:728-730.
11. Murthy KK: Passive protection against human immunodeficiency virus infection. AIDS Res Rev 1993;3:243-254.
12. Prince AM, Reesink H, Pascual D, Horowitz B, Hewlett I, Murthy KK, Cobb KE, and Eichberg JW: Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res Hum Retrovir 1991;7:971-973.
13. Ward RHR, Capon DJ, Jett CM, Murthy KK, Mordenti J, Lucas C, Frie SW, and Prince AM: HIV-1IIIB infection in chimpanzees by CD4 immunoadhesion. Nature (London) 1991;352:434-436.
14. Fultz PN: Nonhuman primate models for AIDS. Clin Infect Dis 1993;17:s230-s235.
15. Levy JA, Hoffman AD, Kramer SM, Landis JA, Shimabukuro JM, and Oshiro LS: Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 1994;225:840-842.
16. Cheng-Mayer C, Seto D, Tateno M, and Levy JA: Biologic features of HIV that correlate with virulence in the host. Science 1988;240:80-82.
17. Cheng-Mayer C, Homsy JM, Evans LA, and Levy JA; Identification of HIV subtypes with distinct patterns of sensitivity to serum neutralization. Proc Natl Acad Sci USA 1988;85:2815-2819.
18. Castro BA, Eichberg JW, Lerche NW, and Levy JA: HIV from experimentally infected chimpanzees: Isolation and characterization. J Med Primatol 1989;18:337-342.
19. McDougal JS, Cort SP, Kennedy MS, Cabridilla CD, Feorino PM, Francis DP, Hicks D, Kalyanaraman VS, and Martin LS: Immunoassay for the detection and quantitation of infectious human retrovirus, lymphadenopathy-associated virus (LAV). J Immunolog Methods 1985;76:171-183.
20. Mackewicz CE, Ortega HW, and Levy JA: CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest 1991;87:1462-1466.
21. Mackewicz C, and Levy JA: CD8+ cell anti-HIV activity: Nonlytic suppression of virus replication. AIDS Res Hum Retrovir 1992;8:1039-1050.
22. Hoffman AD, Banapour B, and Levy JA: Characterization of the AIDS-associated retrovirus reverse transcriptase and the optimal conditions for its detection in virions. Virology 1985;147:326-335.
23. Pan L-Z, Cheng-Mayer C, and Levy JA: Patterns of antibody response in individuals infected with the human immunodeficiency virus. J Infect Dis 1987;155:626-632.
24. Rogers MF, Ou C-Y, Rayfield M, Thomas PA, Schoenbaum EE, Abrams E, Krasinski K, Selwyn PA, Moore J, Kaul A, Grimm K, Bamji M, and Schochetman G: Use of the polymerase chain reaction for early detection of the proviral sequences of human immunodeficiency virus in infants born to seropositive mothers. N Engl J Med 1989;320:1649-1654.
25. Ou C-Y, McDonough S-H, and Cabanas D: Rapid and quantitative detection of enzymatically amplified HIV-1 DNA using chemiluminescent oligonucleotide probes. AIDS Res Hum Retroviruses 1990;6:1323-1329.
26. Ou C-Y, Ciesielski CA, Myers G, Bandea CI, Luo C-H, Korber BTM, Mullins JI, Schochetman G, Berkelman RL, Economou AN, Witte JJ, Furman LJ, Satten GA, Machines KA, Curran JW, and Jaffe HW: Molecular epidemiology of HIV transmission in a dental practice. Science 1992;256:1165-1171.
27. Conrad AJ, Schmid P, Syndulko K, Singer EJ, Nagro RM, Russell JJ, and Tourtellote WW: Quantifying HIV-1 RNA using the polymerase chain reaction on cerebrospinal fluid and serum of seropositive individuals with and without neurological abnormalities. J Acquire Immunodefic Syndr 1995;10:425-435.
28. Evans LA, McHugh TM, Stiles DP, and Levy JA: Differential ability of human immunodeficiency virus isolates to productively infect human cells. J Immunol 1987;138:3415-3418.
29. Castro B, Walker CM, Eichberg JW, and Levy JA: Suppression of human immunodeficiency virus replication by CD8+ cells from infected and uninfected chimpanzees. Cell Immunol 1991;132: 246-255.
30. Lewis MG, Bellah S, McKinnon K, Yalley-Ogunro J, Zack PM, Elkins WR, Desrosiers RC, and Eddy GA: Titration and characterization of two rhesus-derived SIVmac challenge stocks. AIDS Res Hum Retroviruses 1994;10(2):213-220.
31. Daniel MD, Letvin NL, Sehgal PK, Hunsmann G, Schmidt DK, King NW, and Desrosiers RC: Long-term presistent infection of macaque monkeys with the simian immunodeficiency virus. J Gen Virol 1987;68:3183-3189.
32. Javaherian K, Langlois AJ, LaRosa GJ, Profy AT, Bolognesi DP, Herlihy WC, Putney SD, and Matthews TJ: Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science 1990;250:1590-1593.
33. Myers G, Korber B, Wain-Hobson S, Smith RF, and Pavlakis GN: Human Retroviruses and AIDS 1994, I-V. A compilation and analysis of nucleic acid and amino acid sequences. Los Alamos, Los Alamos National Laboratory, 1994.
34. El-Amad Z, Murthy KK, Higgins K, Cobb EK, Haigwood NL, Levy JA, and Steimer KS: Resistance of chimpanzees immunized with recombinant gp120 SF2 to challenge by HIV-1SF2. AIDS 1995;9:1313-1322.
35. Berman PW, Murthy KK, Wrin T, Vennari JC, Cobb EK, Eastman DJ, Champe M, Nakamura GR, Davison D, Powell MF, Bussiere J, Francis DP, Matthews T, Gregory TJ, and Obijeski J: Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. J Infect Dis 1996;173:52-59.
36. SF2 boosting: efficacy testing in chimpanzees. Conference on Advances in AIDS Vaccine Development, Seventh Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, 1994.
37. Girard M, Meignier B, Barre-Sinoussi F, Kieny M-P, Matthews T, Muchmore E, Nara PL, Wei Q, Rimsky L, Weinhold K, and Fultz PN: Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J Virol 1995;69:6239-6248.